A Phase 4 interventional study of Colchicine (Colcrys®) and Placebo in Colchicine, Inflammation in Cardiac Surgery and Post Operative Atrial Fibrillation, sponsored by Ayesha Ather. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Ayesha Ather · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.
Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 20th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 21st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
Elsan · Sites in France
Ages 18+
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2012; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 236 across the 22 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ayesha Ather as lead sponsor.
Ayesha Ather has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies testing colchicine in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05890664Phase 3University Hospital, Basel, SwitzerlandColchicine After Electrocardioversion for Atrial Fibrillation | 2027-03 |
| NCT07287345Ayesha AtherColchicine's Effect on Inflammatory Markers | 2026-12-30 |
| NCT06765356Vivek ReddyPragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing colchicine in Atrial Fibrillation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study wants to see if the medicine colchicine can help lower inflammation and reduce the chance of developing an irregular heartbeat (atrial fibrillation) after heart bypass surgery. Adults having coronary artery bypass surgery (CABG) can join. Participants will be randomly placed into one of two groups: one group will receive colchicine along with usual care, and the other will receive a placebo (a look-alike capsule with no medicine) along with usual care. Everyone will take a study capsule, and neither the patients nor the study team will know which capsule is being given. Everyone in the study will take study capsule, and neither the patients nor the study team will know who is receiving colchicine or placebo. Blood samples and health information will be collected before surgery; at 24, 48, 72, and 96 hours after surgery; and again at 10 days after surgery or at hospital discharge, whichever comes first. The investigators will look at inflammation marker levels, whether atrial fibrillation happens, and any side effects. This small study will help to generate effect size estimates and safety data that will help plan a larger study in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo capsule
Drug: Placebo
colchicine capsule
Drug: Colchicine (Colcrys®)
Colchicine dosing is based on actual body weight and renal function (creatinine clearance). Subjects will initiate study medication (placebo or active drug) 5 days prior to surgery and continue therapy for 10 days postoperatively or until hospital discharge, whichever occurs first. For patients weighing ≥70 kg: If CrCl \>30 mL/min: Colchicine 0.6 mg twice daily If CrCl \<30 mL/min: Colchicine 0.3 mg once daily For patients weighing \<70 kg: If CrCl \>30 mL/min: Colchicine 0.6 mg once daily If CrCl \<30 mL/min: Colchicine 0.3 mg every other day
Placebo dosing is based on actual body weight and renal function (creatinine clearance). Subjects will initiate study medication (placebo or active drug) 5 days prior to surgery and continue therapy for 10 days postoperatively or until hospital discharge, whichever occurs first. For patients weighing ≥70 kg: If CrCl \>30 mL/min: Placebo 0.6 mg twice daily If CrCl \<30 mL/min: Placebo 0.3 mg once daily For patients weighing \<70 kg: If CrCl \>30 mL/min: Placebo 0.6 mg once daily If CrCl \<30 mL/min: Placebo 0.3 mg every other day
Change in Inflammatory markers
markers of inflammation (IL-6, CRP, IL-18, IL-1β, IL-8, and TNF-α) will be measured at predefined time points. Blood samples will be obtained as part of routine clinical care and analyzed using commercially available ELISA assays.
Time frame: Baseline (pre-surgery), 24, 48, 72, 96 hours post-surgery and 10 days postoperatively or at discharge, whichever occurs first.
Rate of post-operative atrial fibrillation (POAF)
Postoperative atrial fibrillation (POAF) incidence will be assessed through daily chart review.
Time frame: Through discharge (up to 15 days)
Number of participants discontinuing treatment
treatment discontinuation rates due to adverse events will be measured
Time frame: Through discharge (up to 15 days)
Change in Liver Function
Assessed as the impact on clinical biomarkers, i.e., ALT, AST in units per liter.
Time frame: Baseline and Post operatively (approximately 24 hours)
Change in creatinine level
Assessed as the impact on clinical biomarkers, i.e., creatinine level in mg/dl
Time frame: Baseline through discharge (up to 15 days)
Creatine kinase level
Assessed as the impact on clinical biomarkers, creatine kinase (i.e., CK level) in units per liter
Time frame: Through discharge (up to 15 days)
Complete blood count (CBC).
Assessed as the impact on clinical biomarker complete blood count (CBC).
Time frame: Through discharge (up to 15 days)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 11 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine